Clinical overview of children with mucopolysaccharidosis type III A and effect of Risperidone treatment on children and their mothers psychological status

Brain and Development

Volumn 32, Issue 2, 2010, Pages 156-161

  Kalkan Ucar, Sema ^a   Ozbaran, Burcu ^a   Demiral, Nagehan ^a   Yuncu, Zeki ^a   Erermis, Serpil ^a   Coker, Mahmut ^a  

^a EGE UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

Author keywords

Children; Mother; Mucopolysaccharidosis IIIA; Psychological status; Risperidone treatment

Indexed keywords

GLUCOSE; HEPARAN SULFATE; LIPID; PROLACTIN; RISPERIDONE;

ANXIETY; ARTICLE; BECK DEPRESSION INVENTORY; BEHAVIOR DISORDER; BODY WEIGHT; CHILD; CHILD AND ADOLESCENT BEHAVIOR DISORDERS SCREENING AND RATING SCALE; CLINICAL ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DEPRESSION; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DISEASE SEVERITY; DISRUPTIVE BEHAVIOR; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GLUCOSE BLOOD LEVEL; HAMILTON ANXIETY SCALE; HUMAN; HYPERACTIVITY; LIPID BLOOD LEVEL; MALE; MENTAL HEALTH; MOTHER CHILD RELATION; OPEN STUDY; OPPOSITIONAL DEFIANT DISORDER; PATIENT MONITORING; PROLACTIN BLOOD LEVEL; PSYCHOLOGICAL RATING SCALE; RANDOMIZED CONTROLLED TRIAL; SANFILIPPO SYNDROME; TREATMENT DURATION;

ADOLESCENT; ANTIPSYCHOTIC AGENTS; CHILD; CHILD BEHAVIOR DISORDERS; CHILD, PRESCHOOL; CROSS-OVER STUDIES; FEMALE; HUMANS; MALE; MOTHERS; MUCOPOLYSACCHARIDOSIS III; PREGNANCY; RISPERIDONE;

EID: 73749086286     PISSN: 03877604     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.braindev.2008.12.010     Document Type: Article

References (23)

1. Neufeld E.F., and Muenzer J. The mucopolysaccharidoses. In: Scriver C.R., Beaudet A.L., Sly W.S., and Valle D. (Eds). The metabolic and molecular bases of inherited disease. 8th ed. (2001), McGraw-Hill, New York 3421-3452
2. Ruijter G.J., Valstar M.J., van de Kamp J.M., van der Helm R.M., Durand S., van Diggelen O.P., et al. Clinical and genetic spectrum of Sanfilippo type C (MPS IIIC) disease in The Netherlands. Mol Genet Metab 93 (2008) 104-111
3. Bax M.C., and Colville G.A. Behaviour in mucopolysaccharide disorders. Arch Dis Child 73 (1995) 77-81
4. Cleary M.A., and Wraith J.E. Management of mucopolysaccharidosis type III. Arch Dis Child 69 (1993) 403-406
5. Valstar M.J., Ruijter G.J., van Diggelen O.P., Poorthuis B.J., and Wijburg F.A. Sanfilippo syndrome: a mini-review. J Inherit Metab Dis 31 (2008) 240-252
6. Jesner O.S., Aref-Adib M., and Coren E. Risperidone for autism spectrum disorder. Cochrane Database Syst Rev 24 (2007) CD005040
7. Kaufman J., Birmaher B., and Brent D. Schedule for affective disorders and schizophrenia for school age children - present and lifetime version (KSADS-PL) initial reliability and validity data. J Am Acad Child Adolesc Psychiatry 36 (1997) 980-988
8. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 4th edition (DSM-IV). Washington, DC: American Psychiatric Association; 1994. p. 103-10.
9. Gökler B., Ünal F., Pehlivanturk F., Kültür E., Akdemir D., and Taner Y. Reliability and validity of schedule for affective disorders and Schizophrenia for school age children-present and lifetime version-Turkish version (K-SADS-PL-T) [in Turkish]. Turk J Child Adolesc Mental Health 11 (2004) 109-116
10. Turgay A. Disruptive behavior disorders child and adolescent screening and rating scales for children, adolescents, parents and teachers (1994), Integrative Therapy Institute Publication, West Blomfield
11. Ercan E.S., Amado S., Somer O., et al. Development of a test battery for the assessment of attention deficit hyperactivity disorder [in Turkish]. Turk J Child Adolesc Psychiatry 8 (2001) 132-144
12. National Institute of Mental Health. CGI (Clinic Global Impression) scale. Psychopharmacology Bull 1985; 21: 839-43.
13. Savasir I., Sezgin N., and Erol N. Ankara Gelisim Tarama Envanteri (AGTE) El Kitabi. 2nd ed. [in Turkish] (1989), Reklamay Lim. Şti., Ankara [p. 1-29]
14. Hamilton M. The assessment of anxiety scales by rating. Br J Med Psychol 32 (1959) 50-55
15. Beck A.T., Ward C.H., Mendelson M., Mock J., and Erbaugh J. An inventory for measuring depression. Arch Gen Psychiatry 4 (1961) 561-571
16. Yazi{dotless}ci{dotless} M.K., Demir B., Tanri{dotless}verdi N., Karaagaoglu E., and Yolac P. Hamilton anxiety rating scale: interrater reliabilty and validity Study. Turk J Psychiatry 9 (1998) 114-117
17. Hisli N. A study on the validity of the Beck depression inventory. Turk Psychol J 6 (1998) 118-123 [in Turkish]
18. Meyer A., Kossow K., Gal A., and Muhlhausen C. Scoring evaluation of the natural course of mucopolysaccharidosis type IIIA (Sanfilippo syndrome type A). Pediatrics 120 (2007) 1255-1261
19. van de Kamp J.J., Niermeijer M.F., von Figura K., and Giesberts M.A. Genetic heterogeneity and clinical variability in the Sanfilippo syndrome (types A, B, and C). Clin Genet 20 (1981) 152-160
20. McCracken J.T., McGough J., Shah B., Cronin P., Hong D., Aman M.G., et al. Risperidone in children with autism and serious behavioral problems. N Engl J Med 347 (2002) 314-321
21. Guerrero J.M., Pozo D., Diaz-Rodriguez J.L., Martinez-Cruz F., and Vela-Campos F. Impairment of the melatonin rhythm in children with Sanfilippo syndrome. J Pineal Res 40 (2006) 192-193
22. Kazdin A.E., and Wassell G. Barrier to treatment participation and therapeutic change among children referred for conduct disorder. J Clin Child Psychol 28 (1999) 160-172
23. Bukstein O.G. Satisfaction with treatment for attention-deficit/hyperactivity disorder. Am J Manag Care 10 (2004) 107-116